These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 36594122)
21. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center. Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902 [TBL] [Abstract][Full Text] [Related]
22. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study. Peng Z; Gao J; Huang L; He Y; Tang H; Zong S; Pei Y; Pei F; Ge J; Liu X; Yue L; Zhou J; Li X; Yue D; Chen Y; Chen C; Wu X; Feng X; Li C Front Immunol; 2024; 15():1426640. PubMed ID: 39253078 [TBL] [Abstract][Full Text] [Related]
23. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia. Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340 [TBL] [Abstract][Full Text] [Related]
24. Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation. Ueda S; Sakata N; Muramatsu H; Sakaguchi H; Wang X; Xu Y; Kojima S; Yamaguchi T; Higa T; Takemura T Int J Hematol; 2014 Nov; 100(5):502-6. PubMed ID: 25047104 [TBL] [Abstract][Full Text] [Related]
25. How I treat juvenile myelomonocytic leukemia. Locatelli F; Niemeyer CM Blood; 2015 Feb; 125(7):1083-90. PubMed ID: 25564399 [TBL] [Abstract][Full Text] [Related]
26. Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML. Mao S; Lin Y; Qin X; Miao Y; Luo C; Luo C; Wang J; Huang X; Zhu H; Lai J; Chen J Br J Haematol; 2024 Jun; 204(6):2332-2341. PubMed ID: 38622924 [TBL] [Abstract][Full Text] [Related]
27. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330 [TBL] [Abstract][Full Text] [Related]
29. [Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia]. Yang WY; Chen XJ; Wang SC; Guo Y; Liu TF; Chang LX; Liu F; Zhu XF Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):1-5. PubMed ID: 25616283 [TBL] [Abstract][Full Text] [Related]
30. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Koike K; Matsuda K Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786 [TBL] [Abstract][Full Text] [Related]
32. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. Lasho T; Patnaik MM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983 [TBL] [Abstract][Full Text] [Related]
33. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720 [TBL] [Abstract][Full Text] [Related]
34. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. Stieglitz E; Ward AF; Gerbing RB; Alonzo TA; Arceci RJ; Liu YL; Emanuel PD; Widemann BC; Cheng JW; Jayaprakash N; Balis FM; Castleberry RP; Bunin NJ; Loh ML; Cooper TM Pediatr Blood Cancer; 2015 Apr; 62(4):629-36. PubMed ID: 25704135 [TBL] [Abstract][Full Text] [Related]
35. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl. Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758 [TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Manabe A; Okamura J; Yumura-Yagi K; Akiyama Y; Sako M; Uchiyama H; Kojima S; Koike K; Saito T; Nakahata T; Leukemia; 2002 Apr; 16(4):645-9. PubMed ID: 11960345 [TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology. Honda Y; Tsuchida M; Zaike Y; Masunaga A; Yoshimi A; Kojima S; Ito M; Kikuchi A; Nakahata T; Manabe A Br J Haematol; 2014 Jun; 165(5):682-7. PubMed ID: 24588411 [TBL] [Abstract][Full Text] [Related]
38. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648 [TBL] [Abstract][Full Text] [Related]